A detailed history of Achmea Investment Management B.V. transactions in Exact Sciences Corp stock. As of the latest transaction made, Achmea Investment Management B.V. holds 24,125 shares of EXAS stock, worth $1.19 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
24,125
Previous 10,665 126.21%
Holding current value
$1.19 Million
Previous $450,000 265.33%
% of portfolio
0.03%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$42.43 - $70.83 $571,107 - $953,371
13,460 Added 126.21%
24,125 $1.64 Million
Q4 2023

Feb 12, 2024

SELL
$59.06 - $75.72 $269,077 - $344,980
-4,556 Reduced 29.93%
10,665 $789,000
Q3 2023

Nov 06, 2023

SELL
$65.94 - $99.04 $21,166 - $31,791
-321 Reduced 2.07%
15,221 $1.04 Million
Q2 2023

Jul 24, 2023

BUY
$62.68 - $95.05 $285,570 - $433,047
4,556 Added 41.47%
15,542 $1.46 Million
Q1 2023

May 04, 2023

BUY
$47.19 - $70.77 $503,281 - $754,762
10,665 Added 3322.43%
10,986 $745,000
Q1 2022

May 16, 2022

SELL
$57.56 - $82.54 $272,489 - $390,744
-4,734 Reduced 93.65%
321 $22,000
Q3 2021

Nov 12, 2021

BUY
$90.24 - $124.05 $28,967 - $39,820
321 Added 6.78%
5,055 $482,000
Q1 2021

May 11, 2021

BUY
$116.57 - $155.01 $551,842 - $733,817
4,734 New
4,734 $624,000
Q3 2020

Nov 02, 2020

SELL
$72.92 - $102.01 $1.86 Million - $2.6 Million
-25,500 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$37.9 - $104.44 $500,507 - $1.38 Million
13,206 Added 107.42%
25,500 $1.48 Million
Q2 2019

Aug 06, 2019

BUY
$89.51 - $118.04 $1.1 Million - $1.45 Million
12,294 New
12,294 $1.45 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.73B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Achmea Investment Management B.V. Portfolio

Follow Achmea Investment Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Achmea Investment Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Achmea Investment Management B.V. with notifications on news.